BOCA RATON, FL — September 16, 2025 — Leads & Copy — LIXTE Biotechnology Holdings (NASDAQ:LIXT) is focusing on its lead compound, LB-100, a clinical-stage inhibitor of protein phosphatase 2A (PP2A), an enzyme cancers use to survive treatment.
LB-100 disables cancer’s emergency escape route, leaving cells defenseless against therapy by inhibiting PP2A and disrupting cancer’s ability to repair itself.
Through a partnership with GSK, LIXTE is studying LB-100 in ovarian clear-cell carcinoma alongside Dostarlimab, with GSK funding the trial. Roche is providing atezolizumab and trial funding for a study in microsatellite stable colorectal cancer at the Netherlands Cancer Institute.
This summer, LIXTE purchased a $2.6 million portfolio of digital assets, positioning nearly half of its treasury in this new category as a forward-looking balance sheet strategy.
The company has also reshaped its leadership team, including a new CFO and new board members with financial and operational expertise.
Contact: info@hawkpointmedia.com
Source: Lixte Biotechnology Holdings, Inc.
